FIAF Blocking Peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Z1P8 |
---|---|
Other Accession | BAC25242 |
Gene ID | 57875 |
Calculated MW | 45538 Da |
Gene ID | 57875 |
---|---|
Application & Usage | The peptide is used for blocking the antibody activity of FIAF. It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30-60 minutes at 37°C. |
Other Names | Angiopoietin-related protein 4, 425O18-1, Angiopoietin-like protein 4, Fasting-induced adipose factor, Hepatic fibrinogen/angiopoietin-related protein, HFARP, Secreted protein Bk89, Angptl4, Farp, Fiaf, Ng27 |
Target/Specificity | FIAF |
Formulation | 50 µ (0.5 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 50% glycerol, 1% BSA and 0.02% thimerosal. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | FIAF Blocking Peptide is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Angptl4 |
---|---|
Synonyms | Farp, Fiaf {ECO:0000303|PubMed:10862772} |
Function | Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:15837923, PubMed:17609370, PubMed:29899519). May also play a role in regulating glucose homeostasis and insulin sensitivity (PubMed:15837923, PubMed:29899519). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage (PubMed:14583458, PubMed:17130448, PubMed:21832056). Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) (By similarity). Depending on context, may modulate tumor-related angiogenesis (Probable). |
Cellular Location | Secreted. Secreted, extracellular space, extracellular matrix {ECO:0000250|UniProtKB:Q9BY76}. Note=The unprocessed form interacts with the extracellular matrix. This may constitute a dynamic reservoir, a regulatory mechanism of the bioavailability of ANGPTL4. {ECO:0000250|UniProtKB:Q9BY76} |
Tissue Location | Detected in liver and kidney (PubMed:10698685, PubMed:17609370). Predominantly expressed in adipose tissue and is strongly up-regulated by fasting in white adipose tissue and liver |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.